We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 13, 2017

Clinical Efficacy and Safety of Achieving Very Low LDL Cholesterol With the PCSK9 Inhibitor Evolocumab

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Clinical Efficacy and Safety of Achieving Very Low LDL-Cholesterol Concentrations With the PCSK9 Inhibitor Evolocumab: A Prespecified Secondary Analysis of the FOURIER Trial
Lancet 2017 Aug 25;[EPub Ahead of Print], RP Giugliano, TR Pedersen, JG Park, GM De Ferrari, ZA Gaciong, R Ceska, K Toth, I Gouni-Berthold, J Lopez-Miranda, F Schiele, F Mach, BR Ott, E Kanevsky, AL Pineda, R Somaratne, SM Wasserman, AC Keech, PS Sever, MS Sabatine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading